UK-based pharmaceutical company Phagenesis closed its €7m ($9.3m) of series B funding yesterday with Inventages, a life sciences firm backed by Switzerland-based food and nutrition corporation Nestlé, leading the round. Founded in 2007 after it span off from research performed at the University of Manchester, Phagenesis raised £2m ($3.1m) in a September 2010 series A…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
